트랜스티레틴 아밀로이드증 치료 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 7.8%로 80억 4,000만 달러로 성장합니다. 예측 기간 중의 성장은 치료 파이프라인의 확대, 유전자 스크리닝 증가, 희귀질환에 대한 세계 인식 개선 노력, 맞춤형 의료 접근, 치료 접근성 향상 등에 기인할 것으로 보입니다. 예측 기간 중 주요 동향으로는 병용요법의 등장, 의약품 개발을 위한 전략적 파트너십, 말초 및 심장 증상 표적화, 환자 교육 프로그램 시행, 치료 가이드라인에 실제 임상적 증거를 반영하는 것 등이 있습니다.
연구개발(R&D) 투자 증가가 트랜스티레틴 아밀로이드증 치료제 시장 성장의 원동력이 될 것으로 예상됩니다. R&D 투자에는 과학적 지식 향상, 신기술 개발, 혁신적인 제품 개발, 기존 프로세스 강화에 할당되는 재원이 포함됩니다. R&D에 대한 자금 지원 강화는 트랜스실레틴아밀로이드증에 대한 새로운 치료법의 발견과 발전을 촉진할 수 있습니다. 이러한 접근법에는 선구적인 약물, 유전자 치료, 정밀의료 기술 등이 포함되며, 환자들에게 보다 효과적이고 표적화된 치료 옵션을 제공할 수 있습니다. 예를 들어 미국에 본사를 둔 바이오 제약사 Alnylam Pharmaceuticals는 2021년 79만 2,156달러에서 2022년 88만 3,015달러로 11.49%의 성장률을 보일 것으로 예상하고 있습니다. 이처럼 연구개발 투자 확대가 트랜스티레틴 아밀로이드증 치료제 시장의 성장을 가속할 것으로 예상됩니다.
고령화 인구의 확대는 트랜스티레틴 아밀로이드증 치료제 시장의 성장을 크게 촉진하는 요인이 될 것으로 보입니다. 고령화는 출산율 감소와 평균 수명 연장으로 인한 평균 연령 증가를 특징으로 하는 인구 통계학적 변화를 의미합니다. 노화는 트랜스티레틴 아밀로이드증(ATTR)의 실질적인 위험 요소이며, 인구가 고령화됨에 따라 이 질환과 관련된 사례의 유병률이 증가합니다. 그 결과, 치료가 필요한 환자가 증가하고 있습니다. 예를 들어 세계보건기구(WHO)의 2022년 10월 보고서에 따르면 전 세계 모든 국가에서 노인 인구의 양과 비율이 급증하고 있으며, 2030년에는 전 세계 인구 6명 중 1명이 60세 이상이 될 것으로 예상됩니다. 따라서 고령화 인구의 급격한 증가는 트랜스티레틴 아밀로이드증 치료제 시장의 성장을 주도하고 있습니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 트랜스티레틴 아밀로이드증 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
- 최종 용도 산업의 분석
- 세계의 트랜스티레틴 아밀로이드증 치료 시장 : 성장률 분석
- 세계의 트랜스티레틴 아밀로이드증 치료 시장의 실적 : 규모와 성장, 2019-2024
- 세계의 트랜스티레틴 아밀로이드증 치료 시장의 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 트랜스티레틴 아밀로이드증 치료 TAM(Total Addressable Market)
제6장 시장 세분화
- 세계의 트랜스티레틴 아밀로이드증 치료 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 트랜스티레틴 아밀로이드증 다발 신경장애(ATTR-PN)
- 트랜스티레틴 아밀로이드증 심근증(ATTR-CM)
- 세계의 트랜스티레틴 아밀로이드증 치료 시장 : 약물별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- Tafamidis
- Patisiran
- Inotersen
- 기타 약물
- 세계의 트랜스티레틴 아밀로이드증 치료 시장 : 테라피별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 표적치료
- 지지요법
- 파이프라인 테라피
- 세계의 트랜스티레틴 아밀로이드증 치료 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 병원 약국
- 전문 약국
- 소매 약국
- 온라인 약국
- 세계의 트랜스티레틴 아밀로이드증 치료 시장, 트랜스티레틴 아밀로이드증 다발 신경장애(ATTR-PN)의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 초기 단계 ATTR-PN
- 상급 단계 ATTR-PN
- 세계의 트랜스티레틴 아밀로이드증 치료 시장, 심근증을 수반하는 트랜스티레틴 아밀로이드증(ATTR-CM)의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 경도 ATTR-CM
- 중도 ATTR-CM
- 고도 ATTR-CM
제7장 지역별·국가별 분석
- 세계의 트랜스티레틴 아밀로이드증 치료 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 트랜스티레틴 아밀로이드증 치료 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 트랜스티레틴 아밀로이드증 치료 시장 : 경쟁 구도
- 트랜스티레틴 아밀로이드증 치료 시장 : 기업 개요
- Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
- Abbvie Inc Overview, Products and Services, Strategy and Financial Analysis
- Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
- GSK Plc
- Novo Nordisk A/S
- Merck & Co. Inc
- Astellas Pharma Inc.
- Alexion Pharmaceuticals Inc.
- Alnylam Pharmaceuticals Inc
- PTC Therapeutics
- Ionis Pharmaceuticals
- Prothena Corporation plc
- BridgeBio Pharma Inc.
- Sorrento Therapeutics Inc.
- Intellia Therapeutics
- Akcea Therapeutics Inc.
- Eidos Therapeutics Inc
- Acrotech Biopharma Inc
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 트랜스티레틴 아밀로이드증 치료 시장 2029 : 새로운 기회를 제공하는 국가
- 트랜스티레틴 아밀로이드증 치료 시장 2029 : 새로운 기회를 제공하는 부문
- 트랜스티레틴 아밀로이드증 치료 시장 2029 : 성장 전략
제36장 부록
KSA
Transthyretin amyloidosis is a gradually progressing condition marked by the accumulation of abnormal protein deposits in the body's organs and tissues. Treatment for transthyretin amyloidosis involves various medical interventions and therapeutic strategies aimed at managing and alleviating the impacts of this condition.
The primary categories of transthyretin amyloidosis treatment include transthyretin amyloidosis with polyneuropathy (ATTR-PN) and transthyretin amyloidosis with cardiomyopathy (ATTR-CM). ATTR-PN involves the abnormal deposition of transthyretin protein in nerves, resulting in peripheral neuropathy and other neurological symptoms. Treatment options for these conditions include drugs such as tafamidis, patisiran, inotersen, as well as targeted therapy, supportive therapy, and pipeline therapies. These treatments are made available through various distribution channels, including hospital pharmacies, specialty pharmacies, retail pharmacies, and online pharmacies.
The transthyretin amyloidosis treatment market research report is one of a series of new reports from The Business Research Company that provides transthyretin amyloidosis treatment market statistics, including transthyretin amyloidosis treatment industry global market size, regional shares, competitors with a transthyretin amyloidosis treatment market share, detailed transthyretin amyloidosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the transthyretin amyloidosis treatment industry. This transthyretin amyloidosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future- scenario of the industry.
The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $5.52 billion in 2024 to $5.95 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, collaboration in research.
The transthyretin amyloidosis treatment market size is expected to see strong growth in the next few years. It will grow to $8.04 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to expanded therapeutic pipeline, increased genetic screening, global efforts for rare disease awareness, personalized medicine approaches, improved access to treatment. Major trends in the forecast period include emergence of combination therapies, strategic partnerships for drug development, focus on targeting peripheral and cardiac manifestations, implementation of patient education programs, incorporation of real-world evidence in treatment guidelines.
Increased investments in research and development (R&D) are projected to be the driving force behind the growth of the transthyretin amyloidosis treatment market. R&D investments encompass financial resources allocated towards advancing scientific knowledge, developing new technologies, creating innovative products, and enhancing existing processes. Augmented funding in R&D endeavors facilitates the discovery and advancement of novel treatment methodologies for transthyretin amyloidosis. These approaches include pioneering drugs, gene therapies, and precision medicine techniques, which offer patients more effective and targeted treatment options. For instance, Alnylam Pharmaceuticals, a US-based biopharmaceutical company, elevated its research and development investment from $792,156 in 2021 to $883,015 in 2022, indicating an 11.49% growth. Thus, the escalating investment in research and development is anticipated to propel the growth of the transthyretin amyloidosis treatment market.
The expanding demographic of the aging population is poised to be a significant driver of growth in the transthyretin amyloidosis treatment market. An aging population signifies a demographic shift characterized by an increased median age due to declining fertility rates and longer life expectancies. Age is a substantial risk factor for transthyretin amyloidosis (ATTR), and as the population ages, the prevalence of cases pertaining to this condition rises. Consequently, there is a growing pool of patients necessitating treatment. For example, according to the World Health Organization's October 2022 report, every country globally is witnessing an upsurge in both the quantity and proportion of older individuals in the population. By 2030, it's projected that 1 in 6 people worldwide will be aged 60 years or older. Hence, the burgeoning demographics of the aging population are steering the growth of the transthyretin amyloidosis treatment market.
Leading companies within the transthyretin amyloidosis treatment sector are prioritizing the development of innovative and specialized therapies, notably orphan drugs, aiming to improve patient outcomes and broaden treatment options. Orphan drugs such as Eplontersen are specifically tailored to address transthyretin amyloidosis, often receiving regulatory advantages to facilitate their development. For instance, Ionis Pharmaceuticals, Inc., a Canada-based biotechnology research company, obtained Food and Drug Administration (FDA) approval for a new drug application concerning Eplontersen in March 2023. Eplontersen, an experimental orphan drug, is intended for the treatment of familial transthyretin-mediated amyloid, which leads to progressive polyneuropathy. Functioning as a pharmaceutical agent, Eplontersen is designed to decrease transthyretin (TTR) protein synthesis, targeting both hereditary and non-hereditary variations of ATTR amyloidosis (amyloid transthyretin amyloidosis). The FDA had granted Eplontersen orphan drug designation in 2022.
In April 2024, BridgeBio Pharma, a US-based biotechnology firm, entered into a collaboration with Bayer to address transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe. As part of the agreement, Bayer will have exclusive rights to commercialize the drug, while BridgeBio will receive up to $310 million in payments and royalties. This partnership increases the likelihood of acoramidis becoming available for patients affected by this serious condition. Bayer is a Germany-based life science company.
Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc., Abbvie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Novo Nordisk A/S, Merck & Co. Inc., Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation PLC, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc., Acrotech Biopharma Inc., Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc., Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A
North America was the largest region in the transthyretin amyloidosis treatment market in 2024. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the transthyretin amyloidosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The transthyretin amyloidosis treatment market consists of revenues earned by entities by providing biopsy, echocardiography, genetic testing, and imaging studies. The market value includes the value of related goods sold by the service provider or included within the service offering. The transthyretin amyloidosis treatment market also includes sales of tolcapone, and diflunisal. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Transthyretin Amyloidosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on transthyretin amyloidosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for transthyretin amyloidosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The transthyretin amyloidosis treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN); Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- 2) By Drug: Tafamidis; Patisiran; Inotersen; Other Drugs
- 3) By Therapy: Targeted Therapy; Supportive Therapy; Pipeline Therapy
- 4) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies; Retail Pharmacies; Online Pharmacies
- Subsegments:
- 1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN; Advanced-Stage ATTR-PN
- 2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM; Moderate ATTR-CM; Severe ATTR-CM
- Companies Mentioned: Pfizer Inc; Abbvie Inc; Sanofi S.A.; Bristol Myers Squibb Company; AstraZeneca plc
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Transthyretin Amyloidosis Treatment Market Characteristics
3. Transthyretin Amyloidosis Treatment Market Trends And Strategies
4. Transthyretin Amyloidosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Transthyretin Amyloidosis Treatment Growth Analysis And Strategic Analysis Framework
- 5.1. Global Transthyretin Amyloidosis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Transthyretin Amyloidosis Treatment Market Growth Rate Analysis
- 5.4. Global Transthyretin Amyloidosis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Transthyretin Amyloidosis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Transthyretin Amyloidosis Treatment Total Addressable Market (TAM)
6. Transthyretin Amyloidosis Treatment Market Segmentation
- 6.1. Global Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN)
- Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- 6.2. Global Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tafamidis
- Patisiran
- Inotersen
- Other Drugs
- 6.3. Global Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Targeted Therapy
- Supportive Therapy
- Pipeline Therapy
- 6.4. Global Transthyretin Amyloidosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Specialty Pharmacies
- Retail Pharmacies
- Online Pharmacies
- 6.5. Global Transthyretin Amyloidosis Treatment Market, Sub-Segmentation Of Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Early-Stage ATTR-PN
- Advanced-Stage ATTR-PN
- 6.6. Global Transthyretin Amyloidosis Treatment Market, Sub-Segmentation Of Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Mild ATTR-CM
- Moderate ATTR-CM
- Severe ATTR-CM
7. Transthyretin Amyloidosis Treatment Market Regional And Country Analysis
- 7.1. Global Transthyretin Amyloidosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Transthyretin Amyloidosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Transthyretin Amyloidosis Treatment Market
- 8.1. Asia-Pacific Transthyretin Amyloidosis Treatment Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Transthyretin Amyloidosis Treatment Market
- 9.1. China Transthyretin Amyloidosis Treatment Market Overview
- 9.2. China Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Transthyretin Amyloidosis Treatment Market
- 10.1. India Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Transthyretin Amyloidosis Treatment Market
- 11.1. Japan Transthyretin Amyloidosis Treatment Market Overview
- 11.2. Japan Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Transthyretin Amyloidosis Treatment Market
- 12.1. Australia Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Transthyretin Amyloidosis Treatment Market
- 13.1. Indonesia Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Transthyretin Amyloidosis Treatment Market
- 14.1. South Korea Transthyretin Amyloidosis Treatment Market Overview
- 14.2. South Korea Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Transthyretin Amyloidosis Treatment Market
- 15.1. Western Europe Transthyretin Amyloidosis Treatment Market Overview
- 15.2. Western Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Transthyretin Amyloidosis Treatment Market
- 16.1. UK Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Transthyretin Amyloidosis Treatment Market
- 17.1. Germany Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Transthyretin Amyloidosis Treatment Market
- 18.1. France Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Transthyretin Amyloidosis Treatment Market
- 19.1. Italy Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Transthyretin Amyloidosis Treatment Market
- 20.1. Spain Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Transthyretin Amyloidosis Treatment Market
- 21.1. Eastern Europe Transthyretin Amyloidosis Treatment Market Overview
- 21.2. Eastern Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Transthyretin Amyloidosis Treatment Market
- 22.1. Russia Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Transthyretin Amyloidosis Treatment Market
- 23.1. North America Transthyretin Amyloidosis Treatment Market Overview
- 23.2. North America Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Transthyretin Amyloidosis Treatment Market
- 24.1. USA Transthyretin Amyloidosis Treatment Market Overview
- 24.2. USA Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Transthyretin Amyloidosis Treatment Market
- 25.1. Canada Transthyretin Amyloidosis Treatment Market Overview
- 25.2. Canada Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Transthyretin Amyloidosis Treatment Market
- 26.1. South America Transthyretin Amyloidosis Treatment Market Overview
- 26.2. South America Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Transthyretin Amyloidosis Treatment Market
- 27.1. Brazil Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Transthyretin Amyloidosis Treatment Market
- 28.1. Middle East Transthyretin Amyloidosis Treatment Market Overview
- 28.2. Middle East Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Transthyretin Amyloidosis Treatment Market
- 29.1. Africa Transthyretin Amyloidosis Treatment Market Overview
- 29.2. Africa Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Transthyretin Amyloidosis Treatment Market Competitive Landscape And Company Profiles
- 30.1. Transthyretin Amyloidosis Treatment Market Competitive Landscape
- 30.2. Transthyretin Amyloidosis Treatment Market Company Profiles
- 30.2.1. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Abbvie Inc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
31. Transthyretin Amyloidosis Treatment Market Other Major And Innovative Companies
- 31.1. GSK Plc
- 31.2. Novo Nordisk A/S
- 31.3. Merck & Co. Inc
- 31.4. Astellas Pharma Inc.
- 31.5. Alexion Pharmaceuticals Inc.
- 31.6. Alnylam Pharmaceuticals Inc
- 31.7. PTC Therapeutics
- 31.8. Ionis Pharmaceuticals
- 31.9. Prothena Corporation plc
- 31.10. BridgeBio Pharma Inc.
- 31.11. Sorrento Therapeutics Inc.
- 31.12. Intellia Therapeutics
- 31.13. Akcea Therapeutics Inc.
- 31.14. Eidos Therapeutics Inc
- 31.15. Acrotech Biopharma Inc
32. Global Transthyretin Amyloidosis Treatment Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Transthyretin Amyloidosis Treatment Market
34. Recent Developments In The Transthyretin Amyloidosis Treatment Market
35. Transthyretin Amyloidosis Treatment Market High Potential Countries, Segments and Strategies
- 35.1 Transthyretin Amyloidosis Treatment Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Transthyretin Amyloidosis Treatment Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Transthyretin Amyloidosis Treatment Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
